Clinical Trial - Trial ChiCTR2200058839
Access comprehensive clinical trial information for ChiCTR2200058839 through Pure Global AI's free database. This Phase 4 trial is sponsored by The Second Affiliated Hospital Of Nanchang University and is currently Not yet recruiting. The study focuses on Rheumatoid arthritis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
ChiCTR2200058839
Phase 4
Not yet recruiting
Trial Details
Chinese Clinical Trial Registry • ChiCTR2200058839
View on Chinese Clinical Trial Registry
Untitled Trial
Evaluation the efficacy and safety of reduced-dose adalimumab in Chinese patients with rheumatoid arthritis (RA): A Multicenter, prospective, parallel-group, real-world study
Study Focus
Sponsor & Location
The Second Affiliated Hospital Of Nanchang University
Biothera Solutions, formerly as Sinoasis Pharma, Ltd.
China
Timeline & Enrollment
Phase 4
N/A
Apr 30, 2024
ICD-10 Classifications
Rheumatoid arthritis, unspecified
Other rheumatoid arthritis
Other specified rheumatoid arthritis
Rheumatoid arthritis with involvement of other organs and systems
Seronegative rheumatoid arthritis
Data Source
Chinese Clinical Trial Registry
ChiCTR2200058839
Non-Device Trial